The nonribosomal peptide/polyketide hybrid colibactin can be considered a bacterial virulence factor involved in extraintestinal infection and also a procarcinogen. Nevertheless, and despite its genotoxic effect, colibactin expression can also inhibit bacterial or tumor growth and correlates with probiotic anti-inflammatory and analgesic properties. Although the biological function of this natural compound has been studied extensively, our understanding of the regulation of colibactin expression is still far from complete. We investigated in detail the role of regulatory elements involved in colibactin expression and in the growth conditions that promote colibactin expression. In this way, our data shed light on the regulatory mechanisms involved in colibactin expression and may support the expression and purification of this interesting nonribosomal peptide/polyketide hybrid for further molecular characterization.
KEYWORDS: secondary metabolite, polyketide, cytopathic effect, RNA-seq, VNTR
ABSTRACT
Colibactin is a nonribosomal peptide/polyketide hybrid natural product expressed by different members of the Enterobacteriaceae which can be correlated with induction of DNA double-strand breaks and interference with cell cycle progression in eukaryotes. Regulatory features of colibactin expression are only incompletely understood. We used Escherichia coli strain M1/5 as a model to investigate regulation of expression of the colibactin determinant at the transcriptional level and to characterize regulatory elements located within the colibactin pathogenicity island itself. We measured clbR transcription in vitro and observed that cultivation in defined minimal media led to increased colibactin expression relative to rich media. Transcription of clbR directly responds to iron availability. We also characterized structural DNA elements inside the colibactin determinant involved in ClbR-dependent regulation, i.e., ClbR binding sites and a variable number of tandem repeats located upstream of clbR. We investigated the impact of clbR overexpression or deletion at the transcriptome and proteome levels. Moreover, we compared global gene regulation under these conditions with that occurring upon overexpression or deletion of clbQ, which affects the flux of colibactin production. Combining the results of the transcriptome and proteome analyses with indirect measurements of colibactin levels by cell culture assays and an approximate quantification of colibactin via the second product of colibactin cleavage from precolibactin, N-myristoyl-d-asparagine, we demonstrate that the variable number of tandem repeats plays a significant regulatory role in colibactin expression. We identify ClbR as the only transcriptional activator known so far that is specific and essential for efficient regulation of colibactin production.
IMPORTANCE The nonribosomal peptide/polyketide hybrid colibactin can be considered a bacterial virulence factor involved in extraintestinal infection and also a procarcinogen. Nevertheless, and despite its genotoxic effect, colibactin expression can also inhibit bacterial or tumor growth and correlates with probiotic anti-inflammatory and analgesic properties. Although the biological function of this natural compound has been studied extensively, our understanding of the regulation of colibactin expression is still far from complete. We investigated in detail the role of regulatory elements involved in colibactin expression and in the growth conditions that promote colibactin expression. In this way, our data shed light on the regulatory mechanisms involved in colibactin expression and may support the expression and purification of this interesting nonribosomal peptide/polyketide hybrid for further molecular characterization.
INTRODUCTION
Certain members of the family of Enterobacteriaceae are able to produce the hybrid nonribosomal peptide/polyketide natural product colibactin (1, 2). The ability to express this cyclomodulin has so far been described in strains of Escherichia coli, Citrobacter koseri, Klebsiella pneumoniae, and Klebsiella aerogenes (formerly known as Enterobacter aerogenes). Many colibactin-positive isolates are pathogenic, but commensal fecal strains can express this compound as well, and even certain probiotic traits have been correlated with the presence of the so-called pks island harboring the colibactin determinant (3, 4). This 54-kb island comprises 19 genes, encoding products required for the biosynthesis and transport of functional colibactin (2). Colibactin has been shown to be a virulence factor (VF) of extraintestinal pathogenic E. coli (ExPEC) strains (5–7), but, due to its ability to cause DNA double-strand breaks, DNA cross-links, and chromosome instability (8–11) together with its presence in E. coli strains isolated from biopsy specimens of colorectal cancer patients (12, 13), it is also discussed as a procarcinogen (14). At the same time, colibactin expression was reported to inhibit bacterial or tumor growth (10, 15). An alternative function as a bacteriocin has also been discussed (16). Experimental evidence has been provided indicating that colibactin expression is linked to probiotic anti-inflammatory (4) and analgesic (17) activities of E. coli Nissle 1917 (EcN). Furthermore, components of the colibactin biosynthesis machinery are also involved in microcin M and H47 biosynthesis (3). Extensive efforts have been invested into the elucidation of the biosynthesis pathway, structure, and mode of action of this secondary metabolite (11, 18–20) in order to understand its biological function (21).
Colibactin biosynthesis by the enzymatic assembly line starts with activation of the nonribosomal peptide synthetases and polyketide synthases by the phosphopantetheinyl transferase ClbA. The first building block channeled into colibactin synthesis is an asparagine, which is processed first by ClbN, followed by ClbB (22), and then the biosynthesis continues with the action of the proteins ClbC-H-I-J-K, incorporating also an aminomalonyl unit generated by the enzymes ClbD-E-F-G (23–25). This intermediate is completed by the action of ClbO-L and then undergoes an editing process mediated by the atypical thioesterase ClbQ (26, 27). It is then transported to the periplasm by the activity of the multidrug and toxic compound extrusion (MATE) transporter ClbM (28), where the precolibactin is finally matured by the peptidase activity of ClbP (29). Colibactin-producing bacteria protect themselves against the DNA damaging activity of this compound by expressing ClbS, a resistance protein, which binds and deactivates colibactin (30). Whether colibactin is subsequently presented on the bacterial cell surface or is released into the medium or actively secreted into host cells remains unclear. In general, the processes involved in the uptake of colibactin in host cells are still largely unknown. Direct bacterium-host cell contact is necessary for internalization of colibactin into host cells, which is limited by the presence of an intact cell membrane or mucus layer (31, 32). Once colibactin is internalized, its ability to cross-link DNA lays the foundation for its cell cycle modifying effect via the induction of DNA double-strand breaks (8). How colibactin finds its way into the nucleus has not been described thus far.
The genetic organization of the pks island exhibits at first sight two distinct features as follows. With the exception of the clbR and clbA genes, all of the clb genes are organized in the same orientation with no or only short (∼50-bp) intergenic regions. The gene cluster coding for the components of the colibactin assembly line starts with clbB and ends with the resistance gene clbS (Fig. 1). Several of these genes are polycistronically transcribed (1, 33). Another smaller but no less important gene cluster is oriented in the opposite direction, is separated by an approximately 400-bp intergenic region from clbB, and codes for the phosphopantetheinyl transferase ClbA and the designated transcriptional activator ClbR (1, 33). Both gene products are necessary for the activation of colibactin production, either by switching on the synthesis proteins or by regulation of colibactin gene transcription. Upstream of these initiating genes, a specific structural element is located, i.e., a region with variable numbers of tandem repeats (VNTR) (Fig. 1). This region consists of an 8-bp nucleotide sequence, 5′-ACAGATAC-3′, and can vary in size, with 2 to 20 repeats of the octanucleotide sequence, depending on the individual bacterial isolate (2). So far, only the numbers of repeats present in the VNTR region have been described to differ between different strains (2), but it is yet not clear whether variations in the size of the VNTR region affect colibactin expression. On the basis of the localization in the intergenic region between the regulatory gene cluster (clbR-A) and the biosynthesis gene cluster (clbB-S), we hypothesize that this genetic element may affect regulation of colibactin expression.
Most of the previous research on colibactin focused on elucidation of the molecular structure and of the mode of action of the active compound or functional intermediates thereof. In contrast, the aim of the present work was to achieve a better understanding of the mechanisms of regulation of colibactin expression and their implications for the biological role of colibactin. The observation that the colibactin biosynthetic pathway can produce different small compounds, such as an analgesic peptide, which can have completely different effects than colibactin itself (14, 15, 17, 22), serves as a great motivator to advance the elucidation of the factors and processes that contribute to the regulation of colibactin expression. Our understanding of the regulation of pks island expression revolves around the activity of its proposed key regulator, ClbR. Until now, ClbR has been described as a LuxR-like protein with a helix-turn-helix DNA-binding motif (33), suggesting that this protein is involved in regulation of pks island transcription. Therefore, our aim in this study was to characterize the function of ClbR as a transcriptional regulator and further details of the regulation of colibactin expression in E. coli.
(Data reported in this study appeared in part in the diploma thesis of M. Selle, the M.Sc. thesis of M. Brinkmann, and the Ph.D. thesis of A. Wallenstein.)
RESULTS
Genome sequence analysis of fecal E. coli isolate M1/5.
For the detailed investigation of regulatory aspects of colibactin expression, we selected E. coli strain M1/5 as our main model organism. This fecal isolate from a healthy volunteer is a reliable colibactin producer and represents the highly relevant group of colibactin-positive E. coli strains of phylogroup B2, which colonize the intestinal tract of many humans. On the basis of the complete genome sequence, E. coli M1/5 was allocated to sequence type 550 (ST550)/clonal complex 14 (CC14) and serotype O75:K5:H5. In addition to the 5,138,587-bp chromosome, the M1/5 genome includes two plasmids, pM1/5-120 (119,964 bp) and pM1/5-30 (29,585 bp) (see Fig. S1 in the supplemental material). Although E. coli M1/5 is a colibactin-positive strain, its genome does not contain many E. coli virulence-associated genes such as those encoding characteristic toxins and adhesins of intestinal or extraintestinal pathogenic E. coli. A group II capsule (serotype K5) gene, multiple fimbrial adhesin operons, several autotransporter-encoding genes, two type six secretion system genes, and different siderophore system genes may contribute to the fitness and competitiveness of E. coli M1/5. Further characteristics regarding the E. coli M1/5 genome content are provided in Table S1 in the supplemental material. Determinants coding for common antibiotic resistance phenotypes in E. coli has been detected in the genome sequence of strain M1/5, which is sensitive to colistin, β-lactams, aminoglycosides, sulfonamide/trimethoprim, phenicols, glycopeptides, tetracyclines, quinolones, rifampin, nitroimidazole, and macrolides.
ClbR is a transcriptional activator of colibactin gene expression.
The clbR gene was originally annotated as a “putative transcriptional regulator” based on the significant similarity of the deduced ClbR amino acid sequence to sequences of transcription regulators of the LuxR/FixJ family (1, 33). The ClbR protein exhibits a high level of similarity to the transcription regulator GerE of Bacillus subtilis. Both GerE and ClbR contain a C-terminal helix-turn-helix (HTH) DNA-binding motif but lack an N-terminal regulatory receiver (REC) domain (34) (Fig. S2). Accordingly, and in contrast to many other LuxR/FixJ family members, both proteins are autonomous effector domain regulators and not response regulators. To gain the first insights into the role of ClbR in regulation of colibactin gene expression, we deleted clbR in E. coli M1/5 and compared the results seen with respect to cytopathic effect (CPE) and DNA damage in infected HeLa cells. In contrast to wild-type strain M1/5, deletion mutant M1/5 ΔclbR neither caused cell cycle arrest as shown by microscopic analysis and flow cytometry (Fig. 2A and B) nor increased levels of phosphorylated histone H2AX in HeLa cells (Fig. 2C). Complementation of E. coli M1/5 ΔclbR with pBAD-clbR restored the ability to block the cell cycle in HeLa cells as well as to induce the DNA damage cascade (Fig. 2).
Furthermore, we transformed previously described reporter strains of E. coli Nissle 1917 (EcN) carrying a transcriptional fusion of the clbR promoter, clbA promoter, clbB promoter, or clbQ promoter and the promoterless luciferase (lux) operon (33) with a plasmid which allows clbR expression under the control of the tetracycline-inducible promoter tetp/o. These strains were cultivated in lysogeny broth (LB), and levels of clbR promoter, clbA promoter, or clbB promoter activity in response to increased ClbR levels were compared by luminescence measurements. This experiment demonstrated that increased ClbR levels resulted in markedly increased promoter activities of the clbR and clbB genes, whereas the clbA promoter activity did not strongly respond to increased ClbR concentrations (Fig. S3). These results indicate that ClbR is a transcriptional (auto)activator of colibactin gene expression.
Promoter activity of clbR and colibactin expression depend on medium composition.
To search for factors and conditions that affect clbR expression, we employed a reporter gene fusion based on the clbR promoter and the promoterless lux operon in E. coli M1/5. We tested different media such as lysogeny broth (LB), terrific broth (TB), M9 medium with and without Casamino Acids, interaction medium (IM), brain heart infusion (BHI), and Todd Hewitt broth (THB) (Fig. 3). Even though the use of each growth medium led to a characteristic pattern of clbR promoter activity, luminescence peaked during the transition from exponential growth to stationary phase except for IM and BHI media, where clbR promoter activity peaked during mid-exponential growth. Expression levels of clbR were higher in poorer than in richer media. The highest values for relative light units (RLU)/optical density at 600 nm (OD600) were observed upon bacterial cultivation in M9 media, and growth in M9 medium with Casamino Acids (M9+CAS) resulted in the most highly defined peak of clbR promoter activity. Cultivation in TB, THB, LB, and BHI medium resulted in a much lower expression level than growth in defined media, such as interaction medium and M9 minimal medium. We also constructed a reporter module based on the frr promoter as a “housekeeping reference” in E. coli M1/5. We measured the clbR and frr promoter activities in E. coli M1/5 upon growth in LB and in M9+CAS medium. The corresponding data are presented in Fig. S4. Under both growth conditions tested, the curve shapes were similar for clbR and frr promoter activities. However, only the clbR promoter activity and not the frr promoter activity increased significantly with growth in M9+CAS medium compared to LB. This supports our observation that clbR promoter activity is specifically induced in poorer media than in LB. On the basis of these findings, we decided to perform all further analyses of colibactin or ClbR expression in E. coli M1/5 in bacterial samples harvested in the late exponential growth phase in M9 medium with Casamino Acids.
To see whether the clbR promoter activity would respond to the growth medium and growth phase to the same extent as that seen with other E. coli isolates, we integrated the same the clbRp-lux reporter module used in E. coli M1/5 into the chromosomal λ-attB site of different model strains, in which colibactin expression has been studied previously, including probiotic strain Nissle 1917, uropathogenic strain UTI89, and newborn meningitis isolates IHE3034 and SP15. We then compared the levels of clbR promoter activity upon cultivation in M9+CAS medium or in LB in these strain backgrounds. In principle, the expression profiles seen with the clbR promoter were very similar to those seen in the other strain backgrounds such as E. coli M1/5; i.e., the promoter activity reached its maximum in the (late) logarithmic-growth phase (Fig. S5). In general, the promoter activity in LB was also significantly lower than in M9+CAS. Interestingly, there were also differences in the clbR promoter activity among the strains; the promoter activity was always higher in E. coli isolates Nissle 1917 and IHE3034 than in E. coli strains UTI89 and SP15. In particular, the levels of promoter activity seen with probiotic strain Nissle 1917 and fecal isolate M1/5 in M9+CAS were very similar (Fig. S5). The results obtained in different strain backgrounds showed that colibactin expression in E. coli reached its maximum in the late exponential-growth phase and was generally higher in poor media than in rich media. Despite basically uniform expression profiles, the levels of strength of clbR promoter activity may differ in different strain backgrounds.
Expression of clbR responds to iron availability.
Previous studies have shown that regulation of colibactin expression responds to iron availability via Fur-dependent and RyhB-dependent regulation of clbA transcription, thus affecting colibactin production (Tronnet et al. [35]). To find out whether expression of the main transcriptional activator of the colibactin genes is also regulated in response to iron availability, we employed the E. coli M1/5 λ-attB::5VNTR-clbRp-lux reporter strain described above to study clbR promoter activity under conditions of iron limitation or in the presence of an increased Fe(III) ion concentration. An increase in ferric iron availability in LB mediated by adding 100 μM FeCl3 as well as iron limitation mediated by adding 0.2 μM deferoxamine had no significant effect either on growth of the E. coli M1/5 reporter strain or on clbR promoter activity (Fig. 4A). Interestingly, addition of 100 μM FeCl3 to M9+CAS resulted in a strong reduction of clbR promoter activity, whereas the presence of 0.2 μM deferoxamine did not affect reporter gene expression during growth (Fig. 4B). These results indicate that ClbR expression is directly altered by the availability of iron also.
ClbR interacts with the clbR-to-clbB intergenic region of the colibactin island.
To investigate whether ClbR interacts with DNA and to identify putative ClbR binding sites within the colibactin island, a series of electrophoretic mobility shift assays (EMSAs) were performed with purified ClbR, focusing on the intergenic region between clbB and clbR. With DNA probes of decreasing sizes, we scanned the clbB-R intergenic region for those parts which interact with the ClbR protein. We identified a ClbR binding site close to clbB and found that the binding motif is located between position bp −40 and position bp −107 upstream of the clbB translational start, since no interaction of ClbR with probes 7, 8, 11, and 12 was detected (Fig. 5A and B). We also studied the interaction of ClbR with the immediate upstream region of its own coding sequence by scanning a 123-bp region upstream of clbR, including the VNTR region, with DNA probes of differing size. ClbR interaction with probes generated from the clbR upstream region were observed with probes 13, 14, and 15 but were no longer observed with probe 16 (Fig. 5C). Accordingly, the DNA stretch upstream of position −2 relative to the clbR translational start is required for ClbR binding. In contrast to the clean shift observed in EMSAs performed with the clbB upstream fragment, the region close to clbR exhibited more-complex interactions with ClbR (Fig. 5C). The clbR gene is preceded by a VNTR region (Fig. 1), and such regions can differ in size. Between 2 and 20 repeats have been described so far (2). We assume that the VNTR region or the overall tertiary structure of this DNA stretch interfered with efforts to reveal a clearer assessment of the migration behavior of the probes designed for this part of the intergenic region between clbB and clbR. Purified ClbR protein did not interact with the probe representing the lacZ promoter region that served as a negative control (Fig. 5D). Accordingly, we have demonstrated that ClbR can interact with the clbB-R intergenic region. We narrowed down the DNA stretch in clbB and also that in the clbR upstream region to which ClbR binds. Our results corroborate the predicted function of ClbR as transcriptional regulator and (auto)activator.
ClbR binding regions and overlapping of clbR and clbB promoter regions.
To further characterize the putative role of the VNTR region as a regulatory element located in the clbR-B intergenic region (Fig. 6A), we investigated the exact transcription start site (TSS) of clbR and clbB by differential transcriptome sequencing (RNA-seq) and compared mapped sequencing reads of untreated and terminator 5′-phosphate-dependent terminator exonuclease (TEX)-treated (enriched for primary transcripts) RNA samples isolated from E. coli strain M1/5 (Fig. 6B and C). Judging on the basis of the number of sequence reads mapped to the chromosomal region close to clbR, this gene is only weakly transcribed. We identified the clbR TSS start 16 bp upstream of the VNTR region, suggesting that this stretch of repeats belongs to the 5′ untranslated region of clbR (Fig. 6D). In contrast, clbB is much more strongly expressed at the transcriptional level than clbR (Fig. 6B and C), and the clbB transcriptional start site was mapped to position −24 relative to the clbB translational start (Fig. 6D). The EMSA and differential RNA-seq data demonstrate that the clbR and clbB transcription start sites overlap the ClbR binding regions within the intergenic region between these two genes (Fig. 5; see also Fig. 6A).
The VNTR region affects clbR expression at the transcriptional level.
To analyze whether a VNTR region of a different size would affect clbR expression, we inserted luciferase-based reporter constructs, which are fused to the clbR upstream region with a VNTR region of either 5 or 20 repeats, into the chromosomal attachment site of bacteriophage λ (λ-attB) and tested for luciferase expression. We measured 2-fold-higher luminescence with the 20-repeat VNTR region than with the VNTR region containing 5 repeats (Fig. 7A and B), suggesting a regulatory impact associated with this particular DNA stretch. We conclude from our reporter gene studies that clbR transcript levels depend on growth phase, resource availability, and length of the VNTR region.
As colibactin expression correlates with the level of available ClbR, we also assessed colibactin production changes in response to the growth medium or size of the VNTR region by quantifying C14-Asn as a by-product of colibactin biosynthesis. For this purpose, the repeat number of the VNTR region had to be modified by scarless mutagenesis, and we generated variants of the native VNTR region comprising either 5 or 19 repeats. The C14-Asn levels produced by isogenic E. coli M1/5 variants carrying a VNTR region with either 5 or 19 repeats upstream of clbR supported our observations made with the chromosomal λ-attB site-inserted luciferase-based reporter fusions comprising 5 or 20 VNTRs. The concentration of C14-Asn increased with increasing VNTR region size and was also higher upon cultivation in M9 medium supplemented with Casamino Acids than in LB (Fig. 7C and D). As a result, our data show that clbR expression is modulated by the composition of the growth medium and by the size of the VNTR region located in the 5′ untranslated region of clbR.
Modulation of colibactin expression via transcriptional activation or altered performance of the production machinery.
To further investigate the role of ClbR as a key regulator of colibactin production as well as of general regulatory aspects of the pks island, we decided to compare the levels of colibactin production seen upon deletion or overexpression of clbR, i.e., in the absence of transcriptional activation or full induction of transcription of the colibactin determinant. Additionally, we tested whether colibactin production is subject to feedback regulation and therefore analyzed the levels of colibactin production seen upon deletion or overexpression of clbQ. ClbQ encodes a type II-family editing thioesterase, which controls the flux of substrates and intermediates during colibactin biosynthesis as well as the overall performance of the production machinery (26). Luminescence measurements performed with different chromosomally inserted reporter constructs that enable analysis of clbR promoter activity supported our finding that overexpression of clbR in trans resulted in increased clbR promoter activity whereas clbQ overexpression in trans had no drastic effect on clbR promoter activity. Furthermore, these luciferase assays also convincingly demonstrate that the size of the VNTR region upstream of clbR promoter affected the clbR transcription level (Fig. 8A). Infection of HeLa cells followed by indirect assessment of colibactin expression via quantification of phosphorylated histone γ-H2AX indicated that clbR overexpression in E. coli strain M1/5 led to a strong increase of γ-H2AX levels, whereas γ-H2AX levels were markedly decreased in the clbR deletion mutant relative to the wild-type strain (Fig. 8B). In contrast, overexpression of clbQ as well as clbQ deletion in E. coli M1/5 reduced the detectable amount of γ-H2AX in infected HeLa cells. Complementation of E. coli M1/5 ΔclbR with pBAD24-tetAp-clbR-rrnBt and complementation of the clbQ deletion mutant of E. coli M1/5 with pBAD24-tetAp-clbQ-rrnBt resulted in γ-H2AX levels in infected HeLa cells that corresponded to those observed upon infection with M1/5 derivatives overexpressing clbR and clbQ, respectively (Fig. 8B). UPLC-HRMS (ultra-high-performance liquid chromatography–high resolution mass spectrometry) measurements of the colibactin biosynthetic by-product C14-Asn confirmed that colibactin production was significantly increased upon overexpression of clbR, whereas clbR deletion, but also clbQ overexpression and clbQ deletion, abolished colibactin expression (Fig. 8C). These results do not support the idea of a potential form of feedback regulation of colibactin gene expression but rather suggest that modulation of the ClbQ protein level reduced the overall performance of the colibactin production machinery or the level of intermediates of the colibactin biosynthesis process.
General impact of colibactin production on the E. coli M1/5 transcriptome and proteome.
To analyze expression of the colibactin determinant at the transcriptomic or proteomic level, and to find out to what extent expression of the colibactin island is integrated into regulatory and metabolic networks, we compared the transcriptome and proteome of E. coli strain M1/5 with those of M1/5 mutants lacking or overexpressing clbR as well as those of the clbQ deletion and overexpressing mutants. In this way, we also aimed to identify ClbR-dependent determinants located outside the pks island as well as candidate genes whose expression might be affected by the activity of the colibactin production machinery or by the availability of metabolites and intermediates related to colibactin production.
To screen for candidate genes which are markedly deregulated in E. coli M1/5 in response to different levels of available ClbR or ClbQ proteins, we pooled three biological replicates of E. coli strain M1/5 or its corresponding mutants and either isolated total RNA for differential RNA-seq analysis or performed gel-free proteomics to analyze the protein content of whole bacterial cells. Transcript levels of only 62 genes were deregulated in at least one of the clbR or clbQ mutants relative to wild-type strain M1/5 with a log2 fold change value less than or equal to −2 or greater than or equal to +2 (Fig. 9A; see also Table S2). Clustering of deregulated genes identified five groups of genes with different expression profiles in the four strains (Fig. 9A). Whereas transcription of the individual genes of the colibactin gene cluster (group 1) was downregulated in the clbR deletion mutant, it was upregulated upon overexpression of clbR (Fig. 9A; see also Fig. S6A and B). The transcriptomic data for individual genes of the colibactin determinant are in good agreement with quantitative reverse transcription-PCR (qRT-PCR) results for clbA, clbR, clbB, and clbQ (Fig. S6A). Apart from that, the transcript levels of group 2 genes involved in histidine biosynthesis were more strongly repressed upon overexpression of clbR and deregulation of clbQ expression than in the clbR mutant. In contrast, transcription of the group 3 genes, which comprise the two iron-regulated sodB and fhuF genes, was specifically reduced in response to clbR overexpression. Deletion and overexpression of clbQ had only a weak effect on transcript levels of the genes in the colibactin gene cluster, except for clbQ and clbS (Fig. S6A and D) but markedly affected, among others, the transcript levels of genes involved in amino acid and secondary metabolite biosynthesis (Fig. 8A, gene groups 2, 4, and 5). Although the transcriptome profiles of strains overexpressing clbR or clbQ could be distinguished from those of the clbR or clbQ deletion mutants, modulation of availability of both ClbR and ClbQ in E. coli M1/5 had similar overall impacts on gene expression at the transcriptional level. Whereas expression of genes involved in histidine biosynthesis was markedly repressed under all four tested conditions, genes required for biosynthesis of secondary metabolites and for aromatic amino acid (tryptophan, tyrosine, phenylalanine) biosynthesis or metabolization were upregulated (Fig. 8A).
In addition, we compared the proteomes of these mutants and identified 145 proteins with log2 fold change values of less than or equal to −2 or greater than or equal to +2 (Fig. 8B; see also Table S2). For six identified proteins, we were also able to describe the corresponding genes as deregulated by RNA-seq. In five cases (ClbR, ClbC, ClbD, ClbF, and ClbQ), these were proteins/genes involved in colibactin biosynthesis. Only one of six deregulated genes (ibpB) and its encoded protein, IbpB, were not directly linked to the colibactin production machinery. As expected, ClbR and ClbQ protein levels were markedly increased upon overexpression of clbR and clbQ, respectively. While the expression levels of most detected Clb proteins did not strongly respond to the availability of ClbQ, some Clb proteins exhibited opposite levels of expression according to whether clbR was deleted or overexpressed (Fig. S6C and E). The global protein expression profiles determined for the deletion of clbR and clbQ as well as for the mutants overexpressing clbR and clbQ were very similar at the protein level also. Cluster analysis indicated that a small number of (group I) proteins was repressed in the four mutants relative to the wild type. The majority of detected deregulated (groups III and IV) proteins were upregulated in the four mutants compared to the wild type (Fig. 8B). Gene Ontology (GO) analysis using E. coli strain CFT073 as reference allowed classification of 38 of 62 deregulated genes and 112 of 145 deregulated proteins detected in the E. coli M1/5 background into functional networks (Table 1). It is interesting that modulation of colibactin production by deletion and by overexpression of either clbR or clbQ had similar effects on gene expression (at the transcriptional or protein level). Although the results of the transcriptome and proteome analyses overlap in only six genes/gene products, the results show that secondary metabolite biosynthesis is influenced by the activity of the colibactin biosynthesis machinery. Several related groups of genes or gene products involved in amino acid (histidine, phenylalanine, tyrosine, and tryptophan) biosynthesis or organonitrogen compound and primary metabolic processes, which are in principle also relevant for polyketide biosynthesis, were deregulated at either the transcriptome or the proteome level. In summary, our observation that the clearly contrasting forms of regulation seen upon clbR deletion and overexpression were detectable only for the colibactin gene cluster supports our view that ClbR is the specific key transcriptional regulator of the colibactin determinant. Our global gene expression data also indicate that colibactin production is functionally connected to pathways involved in biosynthesis or metabolization of particular amino acids and secondary metabolites.
TABLE 1.
Gene or protein | Description | Genes present (%) |
False-discovery rate |
---|---|---|---|
Deregulated genes | |||
GO biological process | |||
GO:0000105 | Histidine biosynthetic process | 77.8 | 2.08E−08 |
GO:0006547 | Histidine metabolic process | 77.8 | 2.08E−08 |
GO:0052803 | Imidazole-containing compound metabolic process | 77.8 | 2.08E−08 |
GO:0008652 | Cellular amino acid biosynthetic process | 8.9 | 6.35E−07 |
GO:1901607 | Alpha-amino acid biosynthetic process | 9.2 | 1.71E−06 |
GO:0009073 | Aromatic amino acid family biosynthetic process | 25.0 | 1.98E−05 |
GO:0009072 | Aromatic amino acid family metabolic process | 21.4 | 3.74E−05 |
GO:1901605 | Alpha-amino acid metabolic process | 5.7 | 8.35E−05 |
GO:0006520 | Cellular amino acid metabolic process | 4.8 | 0.00013 |
GO:1901566 | Organonitrogen compound biosynthetic process | 3.2 | 0.00013 |
GO:0000162 | Tryptophan biosynthetic process | 44.4 | 0.00017 |
GO:0006568 | Tryptophan metabolic process | 36.4 | 0.00026 |
GO:0044283 | Small-molecule biosynthetic process | 3.8 | 0.00035 |
GO:0019438 | Aromatic compound biosynthetic process | 2.7 | 0.00087 |
GO:1901362 | Organic cyclic compound biosynthetic process | 2.5 | 0.0017 |
GO:0006082 | Organic acid metabolic process | 2.8 | 0.0018 |
GO:0044281 | Small-molecule metabolic process | 2.2 | 0.004 |
GO:0044249 | Cellular biosynthetic process | 1.9 | 0.0044 |
GO:1901576 | Organic substance biosynthetic process | 1.9 | 0.0049 |
GO:0034224 | Cellular response to zinc ion starvation | 100.0 | 0.0082 |
GO:0019752 | Carboxylic acid metabolic process | 2.6 | 0.01 |
GO:0018130 | Heterocycle biosynthetic process | 2.3 | 0.0119 |
GO:1901564 | Organonitrogen compound metabolic process | 2.0 | 0.0119 |
GO:0061720 | 6-Sulfoquinovose(1-) catabolic process to glycerine phosphate and 3-sulfolactaldehyde | 50.0 | 0.0168 |
GO:1902776 | 6-Sulfoquinovose(1-) metabolic process | 33.3 | 0.0279 |
GO:0044238 | Primary metabolic process | 1.4 | 0.0436 |
GO:0006725 | Cellular aromatic compound metabolic process | 1.7 | 0.0497 |
KEGG pathway | |||
eco00340 | Histidine metabolism | 87.5 | 6.85E−10 |
eco01230 | Biosynthesis of amino acids | 10.3 | 1.47E−08 |
eco00400 | Phenylalanine, tyrosine, and tryptophan biosynthesis | 28.6 | 1.17E−06 |
eco01110 | Biosynthesis of secondary metabolites | 4.7 | 3.71E−06 |
eco01100 | Metabolic pathways | 2.4 | 0.00087 |
eco00401 | Novobiocin biosynthesis | 50.0 | 0.0057 |
eco01130 | Biosynthesis of antibiotics | 3.3 | 0.0146 |
Deregulated proteins | |||
GO biological process | |||
GO:1901564 | Organonitrogen compound metabolic process | 6.1 | 1.49 × 10−5 |
GO:0071704 | Organic substance metabolic process | 4.8 | 1.49 × 10−5 |
GO:0044238 | Primary metabolic process | 4.8 | 1.49 × 10−5 |
KEGG pathway | |||
eco00523 | Polyketide sugar unit biosynthesis | 50.0 | 0.0325 |
eco00550 | Peptidoglycan biosynthesis | 21.7 | 0.0325 |
eco01100 | Metabolic pathways | 4.8 | 0.0325 |
eco01110 | Biosynthesis of secondary metabolites | 6.3 | 0.0325 |
eco01130 | Biosynthesis of antibiotics | 7.7 | 0.0325 |
eco00521 | Streptomycin biosynthesis | 33.3 | 0.0404 |
DISCUSSION
Although our knowledge of the colibactin biosynthetic mechanism and of the molecular structure of this nonribosomal peptide/polyketide and its mode of action is continuously increasing (11, 19, 20, 22–24, 26, 27, 36, 37), we still have little information on the mechanisms of its regulation. So far, colibactin production and regulation of colibactin gene expression have been mainly analyzed in the context of DNA damage and genotoxicity (1, 8, 9), extraintestinal pathogenic E. coli (ExPEC) pathogenesis (6, 7) but also as factors contributing to the probiotic character of E. coli strain Nissle 1917 (3, 4). Model strains used for the functional characterization of factors involved in colibactin expression are human clinical isolates of ST95 (E. coli O18:K1 newborn meningitis strains IHE3034 and SP15) (1, 35), ST73 (uropathogenic E. coli isolate CFT073) (22), probiotic E. coli strain Nissle 1917 (ST73) (33, 36), or laboratory strain E. coli DH10B (pBeloBAC11-pks) (24, 38, 39). Many E. coli human or murine isolates used for in vivo models of colibactin function have not been characterized in detail at the genomic level (12, 13, 40). To extend the spectrum of well-characterized model strains, we present here the complete genome sequence of human fecal E. coli isolate M1/5, which was isolated from a healthy human individual. This strain represents the large group of colibactin-positive intestinal colonizers of phylogroup B2 without the increased pathogenic potential of ExPEC. E. coli M1/5 (O75:K5:H5) belongs to ST550/CC14 and does not express (cyto)toxins, which can interfere with the phenotypic analysis of colibactin expression in cell culture experiments. This strain also lacks other important E. coli virulence factors, such as type 3 secretion systems as well as typical virulence-related fimbrial adhesins of intestinal and extraintestinal E. coli pathotypes. Comparison of the genome content of E. coli M1/5 with that of other completely sequenced human commensal model strains frequently used for comparative genomics or functional analyses, i.e., E. coli isolates HS (phylogroup A, O9:H4; BioProject accession no. PRJNA13959) (41), SE11 (phylogroup B1, O152:H28; PRJNA18057) (42), IAI1 (phylogroup B1, O8:H19; PRJNA33373) (43), SE15 (phylogroup B2, O150:H5; PRJDA19053) (44), and ED1a (phylogroup B2, O81:H27; PRJNA33409) (43), indicated that these strains differ with respect to the presence of determinants for chaperone-usher fimbriae and other adhesins and of factors involved in serum resistance and iron uptake as well as in gene clusters coding for type 3, type 5, and type 6 secretion systems. E. coli M1/5 is the only isolate among these commensals that carries the colibactin as well as two different flagellar determinants (Flag-1 and Flag-2). Compared to the aforementioned fecal isolates from healthy individuals, the E. coli M1/5 genome comprises the highest number of detected genes that may contribute to fitness of extraintestinal pathogenic E. coli (see Table S1 in the supplemental material).
Our analyses indicate that ClbR is the main transcriptional activator specifically regulating colibactin biosynthesis. ClbR expression directly correlates with the production of functional colibactin. The clbR transcriptional profiles in five fecal and clinical E. coli model isolates were in principle very similar but also exhibited strain-specific differences. The molecular reasons for the different levels of clbR transcription, in particular, the reasons for the perception of the possible presence of inducing or repressing stimuli and their transmission through the interaction of different regulatory elements, are still not understood. It was reported previously that colibactin expression is affected by the bacterial growth state and the composition of the growth medium (33). We also know that the availability of spermidine and other polyamines is required for colibactin production via an as-yet-unknown regulatory mechanism (45). Our reporter gene-based analysis of clbR promoter activity suggests a form of resource-dependent and growth phase-dependent regulation, reflecting distinct clbR expression patterns with varying promoter activities. In most cases, the highest peaks of clbR promoter activity were detected at the transition from late exponential phase to early stationary phase and in less-complex media (Fig. 3; see also Fig. S3 in the supplemental material). Shifts of the colibactin gene expression peak were also observed in our previous study analyzing the impact of different carbon sources on transcription of the colibactin determinant in E. coli strain Nissle 1917 (33). This suggests that transcription of the colibactin determinant is regulated at least in part in response to the availability of metabolites and/or the activity of the central carbon metabolism. The fact that growth in TB, in contrast to other rich media, led to a significantly longer phase of clbR transcription which extended far into the stationary growth phase (Fig. 3) further illustrates that multiple parameters, such as the supply of nutrients and energy, are integrated into the regulation of colibactin expression. This integration is probably achieved by the action of regulators within the framework of regulatory networks. Screenings of random transposon insertion libraries of colibactin-producing strains have not yet identified any regulatory protein that could be involved in adjustment of colibactin expression in response to changing growth conditions.
Importantly, a direct impact on colibactin production via regulation of clbA gene expression has been reported for iron via the ferric uptake regulator (Fur) protein and the RyhB small regulatory RNA (35, 46). Here, we show that expression of the main transcriptional activator of the colibactin determinant is directly affected by iron availability also (Fig. 4). The exact mechanism responsible for iron-dependent regulation of clbR remains to be elucidated. While Fur binding sites have been detected upstream of clbA (35, 46), we did not identify such regions upstream of clbR. The fact that clbR promoter activity was unaffected by increased or decreased iron availability in LB, whereas addition of ferric chloride led to a drastic decrease of clbR promoter activity in minimal medium, may suggest that iron availability rather than availability of nutrients determines the level of clbR expression. Iron and nutrients are highly abundant in rich LB medium such that a decrease or increase in the iron concentration has no effect on clbR expression. In contrast, addition of ferric iron to the minimal medium poorer in iron (and nutrients) led to a strong reduction of clbR promoter activity. A further decrease of iron availability in minimal medium upon addition of the chelator deferoxamine had no effect. This finding suggests that, at least in the LB and M9+CAS medium investigated here, iron availability plays a more important role in the regulation of clbR transcription than nutrient supply. Our results are in accordance with other published data: Transcriptomic analyses indicate that colibactin expression is (at least at the transcriptional level) increased in E. coli upon growth in (iron-limited) urine relative to LB and is detectable during colonization of the intestinal tract and that intestinal inflammation promotes colibactin expression (47–49). Colibactin is considered a virulence factor of newborn meningitis-causing E. coli during sepsis (7) and seems to be important for long-term intestinal colonization (50). A form of regulation of colibactin expression that responds to iron availability in different body niches may support bacterial fitness in the blood or in the context of an Fe(III) ion gradient between the intestinal lumen and the intestinal epithelium, because it ensures fine-tuned colibactin expression under appropriate conditions. The close connection between the metallophore yersiniabactin and colibactin, on both the genomic and regulatory levels (51), is clearly underlined by the iron-dependent regulation of colibactin expression. Deeper insights into the structural diversity of molecules derived from the colibactin pathway, relevant growth conditions, and regulatory mechanisms will help us to better understand the biological role of this interesting and controversial secondary metabolite, whose production has been described to promote cancer but also to be associated with the probiotic character of E. coli (3, 4, 13, 16, 52–57).
ClbR contains a LuxR-type DNA-binding helix-turn-helix (HTH) domain in the C-terminal region which is usually found in response regulators of the LuxR/FixJ family. Classical LuxR/FixJ response regulators possess an N-terminal receiver (REC) domain. This REC domain is responsible for the activation of the response regulator (i) upon phosphorylation by a transmembrane sensor kinase (58), (ii) upon binding of N-acyl homoserine lactones (59, 60), or (iii) upon binding of multiple ligands (MalT) (61). A LuxR-like response regulator lacking a REC domain has been described previously also: transcription factor GerE regulates transcription of spore coat genes in the late sporulation stage in B. subtilis (34, 62). LuxR-type regulators are usually transcriptional activators, although some can act as repressors or, like GerE, can act as both activators and repressors (58). On the basis of its amino acid sequence and predicted structure, ClbR resembles the GerE protein (Fig. S2). As ClbR and GerE lack an N-terminal regulatory REC domain, it is unlikely that ligand binding results in activation of both regulatory proteins. Expression of GerE is regulated at the transcriptional level by a hierarchical cascade involving two different sigma factors and different levels of regulation, including transcription, DNA recombination, and proprotein processing (63). The molecular mechanism responsible for the growth phase-dependent and metabolite-dependent regulation of clbR expression may be as complex as that for GerE and remains to be characterized.
We demonstrated that ClbR binds to an intergenic region that separates the two divergently oriented gene clusters involved in regulation and activation of colibactin expression (clbR and clbA) or in biosynthesis and delivery of the polyketide (clbB to clbS) (Fig. 1, top panel). This intergenic region comprises the promoters of clbR and clbB as well as an additional regulatory element, i.e., the VNTR region, which is located upstream of the clbR translational start site (Fig. 1, bottom panel; see also Fig. 5A). Our results indicate that the size of the VNTR region affects clbR promoter activity and thus colibactin production (Fig. 7 and 8). We assume that the number of repeats and thus the size and secondary structure of the clbR 5′ region can affect clbR transcription as well as transcript stability and the efficacy of translation.
ClbR seems to be a pks island-specific regulator, because our transcriptome analysis in clbR deletion and overexpressing mutants did not indicate that transcription of other genes located outside the pks island was directly dependent on ClbR availability. Only transcription of the clb gene cluster (group 1 genes) changed accordingly with the deletion or overexpression of clbR (Fig. 8A; see also Fig. S6A and B). Otherwise, the few genes which exhibited deregulation in response to deletion or overexpression of clbR (Fig. 8A, group 2 to group 5) responded in fairly similar manners to clbQ deletion and overexpression also. Only the members of a small group of genes (comprising group 1 and group 4), including clbP and clbQ, were upregulated upon clbQ overexpression (Fig. 8A). For cases in which some genes/gene products were able to be clustered according to function, these functionally associated groups are highlighted in Fig. 8. The fact that deletion and overexpression of clbR and clbQ led to very similar global expression profiles at the transcriptome and proteome levels (Fig. 8), in particular, the expression profiles of those genes whose products can be functionally associated with amino acid (histidine, phenylalanine, tyrosines, and tryptophan) and secondary metabolite biosynthesis but also with organonitrogen compound and primary metabolism (gene groups 2 and 5, protein group IV), suggests that these processes are indirectly affected by ClbR and ClbQ and are thus responsive to the colibactin biosynthetic process.
We detected a ClbQ-dependent effect on colibactin expression. Whereas expression of the colibactin determinant at the transcript and protein levels was only weakly affected (Fig. 6; see also Fig. S6D and E), the level of colibactin production, as assessed by the amount of DNA damage and the concentration of the precolibactin cleavage product C14-Asn, was significantly reduced (Fig. 8C). This finding suggests that colibactin production responds to the availability of metabolites, intermediates, or end products of the colibactin biosynthetic process. Both deletion and overexpression of clbQ in E. coli M1/5 resulted in reduced levels of γ-H2AX upon bacterial infection of HeLa cells as well as in significant reduction of C14-Asn levels (Fig. 8B and C). This indicates that interference with the biosynthetic flow mediated by increased unloading of intermediates as well as by clogging of the colibactin biosynthesis pipeline reduces the efficacy of colibactin production. Our results therefore corroborate the in vitro observation that ClbQ facilitates an additional unloading of colibactin synthesis intermediates as previously reported (26). Whereas the absence of ClbQ results in stalled biosynthesis and reduced mature colibactin levels, increased clbQ expression may enhance the release of intermediates from the polyketide assembly line and thus also scale down release of the final colibactin product(s).
Our transcriptome and proteome analyses of the clbQ deletion and overexpressing mutants suggest the existence of a regulatory element affecting clbS expression located within clbQ. While the impact of clbQ deletion or overexpression on clbP transcript levels can be explained by read mapping to the partially overlapping genes clbP and clbQ, increased clbS expression may result from the presence of a promoter region within clbQ which may be affected upon clbQ deletion or overexpression (Fig. S6D). Experimental confirmation of transcriptional start sites within the colibactin determinant will be a key future goal to understand in detail the regulation of colibactin expression.
MATERIALS AND METHODS
Genome sequencing, assembly, annotation, and gene content analysis.
The genome of E. coli M1/5 was sequenced by combining PacBio and Illumina sequencing technologies. For details on the genome sequencing method, see Text S1 in the supplemental material. Genome assembly was performed with the RS_HGAP_Assembly.3 protocol included in SMRT Portal version 2.2.0. For error correction of PacBio HGAP assembly, Illumina short reads were mapped to the assembled chromosome and plasmid sequences using the Burrows-Wheeler Aligner (BWA) (64). A final quality score of QV60 was confirmed using the RS_BridgeMapper.1 protocol. Automated genome annotation was carried out using PGAP (65). Identification of plasmids, serotypes, and acquired resistance genes was performed with the Web-based tools PlasmidFinder (v1.3) (66), SerotypeFinder (v1.1) (67), and ResFinder (v2.1) (68), respectively. We used a stringent identity threshold of 95% to determine plasmids based on replicon sequences. To examine serotypes and acquired resistance genes, sequence identity levels of 85% and 90% were used, respectively. The length requirement was set to a minimum of 60% sequence coverage for both serotyping and identification of resistance genes. For the determination of virulence factors (VFs), we used the E. coli VF collection (v0.1), which comprises 12 distinct VF groups containing 1,154 deduced protein sequences of virulence-associated genes (69).
Bacterial strains, plasmids, genetic manipulations, and media.
Information about the strains and plasmids used in this study is provided in Table 2. All E. coli M1/5 mutants generated and used in this study are based on streptomycin-resistant mutant strain E. coli M1/5 rpsLK42R (51). For the sake of simplicity, we use the shorter description “M1/5” instead of “M1/5 rpsLK42R” in all corresponding mutant designations. Bacterial cultivation was usually performed in lysogeny broth (LB) (10 g liter−1 tryptone, 5 g liter−1 yeast extract, 5 g liter−1 sodium chloride) with shaking at 37°C. If necessary, antibiotics were used at the following concentrations: ampicillin, 100 μg ml−1; chloramphenicol, 15 μg ml−1 and 25 μg ml−1 for low-copy-number and medium-copy-number resistance cassettes, respectively; kanamycin, 50 μg ml−1. l-Arabinose was used at a concentration of 3% (wt/vol) to induce clbR expression from pBAD-clbR. Agar plates were prepared by adding 16 g liter−1 agar.
TABLE 2.
Strain or plasmid | Genotype and/or characteristicsa | Reference or source |
---|---|---|
E. coli strains | ||
DH5α | F−
endA1 hsdR17 supE44 thi-1 recA1 gyrA96 relA1 Δ(argF-lacZYA) U169 (Φ60ΔlacZ M15λ−) |
77 |
Rosetta (DE3) |
E. coli strain B; F−
ompT gal dcm lon? hsdSB(rB−mB−) λ(DE3 [lacI lacUV5-T7p07 ind1 sam7 nin5]) [malB+]K-12(λS) |
Novagen |
One Shot pSLC-242 | Fc
mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 Δ lacX74 recA1 araD139 Δ(araleu)7697 galU galK rpsL (Smr) endA1 nupG |
AddGene/ ThermoFisher |
SY327λpir | λ(lac pro) argE (Am) rif nalA recA56 (λpir) | 78 |
MG1655 | K-12 F− λ ilvG rfb-50 rph-1 | 79 |
M1/5 | Fecal isolate of a healthy individual; pks+, HPI+ | This study |
Nissle 1917 | Fecal isolate of a healthy individual; pks+, HPI+ | 80 |
IHE3034 | Newborn meningitis E. coli isolate; pks+, HPI+ | 81 |
SP15 | Newborn meningitis E. coli isolate; pks+, HPI+ | 82 |
UTI89 | Uropathogenic E. coli isolate; pks+, HPI+ | 83 |
Nissle 1917 λ-attB::5VNTR- clbRp-lux |
Nissle 1917 clbR promoter region containing 5 VNTRs fused with luxABCDE integrated into the λ-attB site |
This study |
IHE3034 λ-attB::5VNTR- clbRp-lux |
IHE3034 clbR promoter region containing 5 VNTRs fused with luxABCDE integrated into the λ-attB site |
This study |
SP15 λ-attB::5VNTR-clbRp-lux | SP15 clbR promoter region containing 5 VNTRs fused with luxABCDE integrated into the λ-attB site |
This study |
UTI89 λ-attB::5VNTR-clbRp-lux | UTI89 clbR promoter region containing 5 VNTRs fused with luxABCDE integrated into the λ-attB site |
This study |
M1/5 rpsLK42R | M1/5 carrying a rpsLK42R mutation; Smr | 51 |
M1/5 rpsLK42R 19VNTR | M1/5 rpsLK42R VNTR region adjusted via scarless mutagenesis to 19 repeats | This study |
M1/5 rpsLK42R 5VNTR | M1/5 rpsLK42R VNTR region adjusted via scarless mutagenesis to 5 repeats | This study |
M1/5 rpsLK42R ΔclbQ | M1/5 rpsLK42R ΔclbQ::FRT | This study |
M1/5 rpsLK42R ΔclbR | M1/5 rpsLK42R ΔclbRA::clbA-FRT | This study |
M1/5 rpsLK42R λ-attB::FRT | FRT site integrated at λ-attB site | This study |
M1/5 λ-attB::20VNTR-clbRp-lux | M1/5 clbR promoter region containing 20 VNTRs fused with luxABCDE integrated into the λ-attB site |
This study |
M1/5 λ-attB::5VNTR-clbRp-lux | M1/5 clbR promoter region containing 5 VNTRs fused with luxABCDE integrated into the λ-attB site |
This study |
Plasmids | ||
pASK75 | Template for tetA promoter cloning | 84 |
pBAD24 | Ampr; araC; araBADp | 85 |
pBAD-clbR | For l-arabinose-inducible expression of clbR from pBAD24 | This study |
pBAD24-clbQ-rrnBt | Template for cloning | This study |
pBAD24-tetAp-clbQ-rrnBt | For constitutive expression of clbQ | This study |
pBAD24-tetAp-clbR-rrnBt | For constitutive expression of clbR | This study |
pBR322 | Template for rrnB terminator cloning | 86 |
pCP20 | Temperature-sensitive origin of replication, encodes Flp recombinase; Ampr, Cmr | 73 |
pEX-K4-tetAp-clbR-rrnBt | Contains synthetic tetAp-clbR-rrnBt insert for clbR expression | This study |
pFuseA-npt | pGP704 derivative for chromosomal integration via a FRT sequence; Kanr; oriR6K; luxABCDE |
33 |
pFuseA-npt-20VNTR-clbRp-lux | pFuseA-npt derivative carrying 20 VNTRs upstream of a clbR promoter-luxABCDE fusion; Kanr; oriR6K |
This study |
pFuseA-npt-5VNTR-clbRp-lux | pFuseA-npt derivative carrying 5 VNTRs upstream of a clbR promoter-luxABCDE fusion; Kanr; oriR6K |
This study |
pGEM-T Easy | TA cloning vector | Promega |
pGEM-T Easy-tetAp-clbR | pGEM-T Easy derivative carrying a tetAp-clbR-rrnBt fusion for inducible expression of clbR; Ampr |
This study |
pKD3 | Template plasmid for amplification of the FRT-flanked chloramphenicol resistance cassette; FRT-cat-FRT; Ampr, Cmr |
71 |
pKD3-ΔclbR1 | pKD3 derivative in which the FRT site upstream of cat has been replaced by a sequence containing the clbR upstream region and the clbA gene; clbRp::clbA- cat-FRT; Ampr, Cmr |
This study |
pKD4 | Template plasmid for amplification of the FRT-flanked kanamycin resistance cassette; Ampr, Kanr |
71 |
pKD4-'clbA | pKD3 derivative with an insertion of the last 524 bp of the clbA gene upstream of the FRT-flanked npt cassette; 'clbA-FRT-npt-FRT; Ampr, Kanr |
This study |
pKD46 | Helper plasmid for l-arabinose-inducible expression of λ-Red recombinase (araC araBp- γ-β-exo); Ampr |
71 |
pSLC-242 | Template plasmid cat cassette for positive selection and relE toxin gene under the control of rhamnose inducible promoter (rhaBp) for negative selection; Cmr |
72 |
pTXB1_clbR | pTXB1 with clbR gene of E. coli Nissle 1917, for IPTG-inducible expression of a ClbR intein/chitin binding domain fusion for purification; Ampr |
This study |
pUC57-Insert_pFuseA-npt_ clbR_20VNTR |
Contains synthetic insert with 20-repeat VNTR-clbRp-lux fusion | This study |
Ampr, ampicillin resistance; Cmr, chloramphenicol resistance; IPTG, isopropyl-β-d-thiogalactopyranoside; Kanr, kanamycin resistance; Smr, streptomycin resistance; HPI, high-pathogenicity island.
For growth experiments, the following media were used: M9 medium (70) either with or without 1 g liter−1 casein hydrolysate (CAS) (12 g liter−1 disodium hydrogen phosphate, 3 g liter−1 potassium dihydrogen phosphate, 2 g liter−1 glucose, 1 g liter−1 ammonium chloride, 0.46 g liter−1 sodium chloride, 0.24 g liter−1 magnesium sulfate, 0.011 g liter−1 calcium chloride, 0.2 mg liter−1 thiamine hydrochloride), terrific broth (TB) (70) (12 g liter−1 tryptone, 24 g liter−1 yeast extract, 5 g liter−1 glycerol, 2.31 g liter−1 monopotassium phosphate, 12.54 g liter−1 dipotassium phosphate), brain heart infusion (BHI) (Fluka, St. Gallen, Switzerland), Todd Hewitt broth (THB) (Oxoid, Wesel, Germany), interaction medium (IM) (Dulbecco’s modified Eagle’s medium [DMEM; Thermo Fisher Scientific, Wesel, Germany] [high glucose, HEPES], supplemented with 1× nonessential amino acids, 2 mM l-alanyl-l-glutamine, 5% [vol/vol] fetal calf serum [FCS]).
For genetic modifications of the bacterial chromosome, the bacteriophage Lambda Red recombinase-dependent approach was used (71), partially refined for scarless mutagenesis (72) or followed by an integrated FRT (FLP recombination target) site/FLP-recombinase-dependent step to generate luciferase-reporter strains (73). The construction of plasmids and mutants is described in detail in Text S1. Oligonucleotides used in this study are given in Table S3 in the supplemental material.
ClbR purification.
The ClbR protein was heterologously expressed as a ClbR-intein-chitin binding domain fusion using a NEB impact system (New England Biolabs). This allowed chitin affinity chromatography and subsequent thiol-mediated self-cleavage of the intein during elution, yielding tag-less ClbR protein. Expression and purification of ClbR are explained in detail in Text S1.
Electrophoretic mobility shift assays (EMSA).
Specific interactions of ClbR with DNA were detected using a digoxigenin (DIG) gel shift kit (second generation; Roche Diagnostics, Mannheim, Germany). Regions of interest containing a potential ClbR binding site were amplified via PCR and subjected to DIG labeling. Labeled probes were incubated with rising concentrations of ClbR and poly[d(I·C)] as a nonspecific competitor probing for specific DNA-ClbR interactions. Bound and unbound probes were separated by native polyacrylamide gel electrophoresis followed by a DNA blotting and were then detected via chemiluminescence according to the manufacturer’s protocol. For details, see Text S1.
Growth-dependent reporter gene assays.
To measure promoter activity via the use of a luminescence reporter (33), we generated reporter fusions by cloning the native clbB-to-clbR intergenic region with a VNTR region comprising either 5 or 20 repeats into the attB locus of E. coli strain M1/5, thereby replacing clbR with luxABCDE. Luciferase expression in the resulting reporter strains was under the control of the clbR promoter. Strains containing the reporter fusion were inoculated 1:100 from overnight cultures in 150 μl in 96-well flat-bottom white polystyrol plates (Greiner Bio-One, Frickenhausen, Germany). OD600 and luminescence levels were measured for 23 h in a Tecan Infinite 200 reader (Tecan Group Ltd., Männedorf, Switzerland) (37°C, shaking for 10 min with amplitude setting 2, luminescence integration time 1 s, in 15-min intervals).
Colibactin cytotoxicity assays.
HeLa cell infection assays were used to analyze the cytotoxic effect of colibactin on mammalian cells via demonstration of megalocytosis and DNA damage (1). The protocols are described in detail in Text S1.
RNA sequencing.
Bacterial cultures were grown as described for the luminescence assays until an OD595 of 0.4 was reached. After pooling of biological replicates, 0.125 volumes of an ethanol-phenol mix (95%:5%) were added and the suspension was incubated 5 min on ice before the bacterial cells were harvested by centrifugation. After the pellet was frozen at –80°C, the cells were thawed and treated with lysozyme by resuspending the pellet in 35 μl Tris-EDTA (TE) buffer that included 85 mg ml−1 lysozyme and incubating the samples for 10 min at room temperature. The sample was subjected to vortex mixing every minute for 10 s. Total RNA was extracted by the use of TRIzol (Invitrogen, Karlsruhe, Germany) according to the manufacturer’s protocol. After DNase treatment and PCR-based quality control, the quality of the RNA samples was further assessed by RNA electrophoresis using a 2200 TapeStation system (Agilent). Strand-specific cDNA libraries processed with and without terminator exonuclease (TEX) treatment to enrich primary transcripts were prepared and sequenced (Illumina NextSeq 500, 1× 75-bp single reads) by Vertis Biotechnologie AG (Freising, Germany). Obtained sequencing data were processed using BWA (64) for mapping of transcripts and ReadXplorer 2 (74) for visualization and utilization of differential gene expression results by the use of DESeq2 (75). Differential RNA-seq, i.e., the comparison of results obtained from samples treated with TEX to those obtained from samples left untreated, allowed detection of primary transcripts and determination transcription start sites (76).
Whole-protein content analysis of RNA sequencing samples.
An aliquot of the bacterial cultures grown for RNA sequencing was also harvested for the analysis of differential protein expression by mass spectrometry. A detailed description of the mass spectrometry-based expression analysis can be found in Text S1.
Quantification of colibactin intermediate N-myristoyl-d-asparagine.
We compared results representing the ability of E. coli strains to produce colibactin upon growth in M9 medium supplemented with Casamino Acids by quantifying the precolibactin cleavage product N-myristoyl-d-asparagine (C14-Asn) (36, 37). Details are provided in Text S1.
Statistical analysis.
Statistical analyses were performed using GraphPad Prism software (version 6.0). The figures show mean values with standard deviations (STDEV.P). Unpaired t tests were used as indicated. A P value of <0.05 was considered statistically significant and is indicated by one asterisk (*). A P value of <0.01 is denoted by two asterisks (**), a P value of <0.001 by three asterisks (***), and a P value of <0.0001 by four asterisks (****).
Data availability.
The complete genome sequence of E. coli M1/5 (the chromosome and plasmids pM1-5_30 and pM1-5_120) has been deposited at NCBI GenBank under accession numbers CP053296 to CP053298. All RNA-seq data files are available from the Gene Expression Omnibus database (accession no. GSE143807).
ACKNOWLEDGMENTS
The work of the Münster team was supported by the Interdisciplinary Center for Clinical Research of the Medical Faculty Münster (Dob2/013/12) and the German Research Foundation (DO789/11-1). The work of the Würzburg team was supported by the German Research Foundation (SFB 479, TP A1).
We thank K. Tegelkamp, O. Mantel, M. Bayer, and A. M. Berg (Münster) as well as S. Severitt and N. Heyer (both DSMZ, Braunschweig) for excellent technical support.
REFERENCES
- 1.Nougayrède JP, Homburg S, Taieb F, Boury M, Brzuszkiewicz E, Gottschalk G, Buchrieser C, Hacker J, Dobrindt U, Oswald E. 2006. Escherichia coli induces DNA double-strand breaks in eukaryotic cells. Science 313:848–851. doi: 10.1126/science.1127059. [DOI] [PubMed] [Google Scholar]
- 2.Putze J, Hennequin C, Nougayrède JP, Zhang W, Homburg S, Karch H, Bringer MA, Fayolle C, Carniel E, Rabsch W, Oelschlaeger TA, Oswald E, Forestier C, Hacker J, Dobrindt U. 2009. Genetic structure and distribution of the colibactin genomic island among members of the family Enterobacteriaceae. Infect Immun 77:4696–4703. doi: 10.1128/IAI.00522-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Massip C, Branchu P, Bossuet-Greif N, Chagneau CV, Gaillard D, Martin P, Boury M, Sécher T, Dubois D, Nougayrède JP, Oswald E. 2019. Deciphering the interplay between the genotoxic and probiotic activities of Escherichia coli Nissle 1917. PLoS Pathog 15:e1008029. doi: 10.1371/journal.ppat.1008029. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Olier M, Marcq I, Salvador-Cartier C, Secher T, Dobrindt U, Boury M, Bacquié V, Pénary M, Gaultier E, Nougayrède JP, Fioramonti J, Oswald E. 2012. Genotoxicity of Escherichia coli Nissle 1917 strain cannot be dissociated from its probiotic activity. Gut Microbes 3:501–509. doi: 10.4161/gmic.21737. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Lu MC, Chen YT, Chiang MK, Wang YC, Hsiao PY, Huang YJ, Lin CT, Cheng CC, Liang CL, Lai YC. 2017. Colibactin contributes to the hypervirulence of pks(+) K1 CC23 Klebsiella pneumoniae in mouse meningitis infections. Front Cell Infect Microbiol 7:103. doi: 10.3389/fcimb.2017.00103. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Marcq I, Martin P, Payros D, Cuevas-Ramos G, Boury M, Watrin C, Nougayrède JP, Olier M, Oswald E. 2014. The genotoxin colibactin exacerbates lymphopenia and decreases survival rate in mice infected with septicemic Escherichia coli. J Infect Dis 210:285–294. doi: 10.1093/infdis/jiu071. [DOI] [PubMed] [Google Scholar]
- 7.McCarthy AJ, Martin P, Cloup E, Stabler RA, Oswald E, Taylor PW. 2015. The genotoxin colibactin is a determinant of virulence in Escherichia coli K1 experimental neonatal systemic infection. Infect Immun 83:3704–3711. doi: 10.1128/IAI.00716-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Bossuet-Greif N, Vignard J, Taieb F, Mirey G, Dubois D, Petit C, Oswald E, Nougayrède JP. 2018. The colibactin genotoxin generates DNA interstrand cross-links in infected cells. mBio 9:e02393-17. doi: 10.1128/mBio.02393-17. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Cuevas-Ramos G, Petit CR, Marcq I, Boury M, Oswald E, Nougayrède JP. 2010. Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells. Proc Natl Acad Sci U S A 107:11537–11542. doi: 10.1073/pnas.1001261107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Vizcaino MI, Engel P, Trautman E, Crawford JM. 2014. Comparative metabolomics and structural characterizations illuminate colibactin pathway-dependent small molecules. J Am Chem Soc 136:9244–9247. doi: 10.1021/ja503450q. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Xue M, Kim CS, Healy AR, Wernke KM, Wang Z, Frischling MC, Shine EE, Wang W, Herzon SB, Crawford JM. 2019. Structure elucidation of colibactin and its DNA cross-links. Science 365:eaax2685. doi: 10.1126/science.aax2685. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Arthur JC, Perez-Chanona E, Mühlbauer M, Tomkovich S, Uronis JM, Fan TJ, Campbell BJ, Abujamel T, Dogan B, Rogers AB, Rhodes JM, Stintzi A, Simpson KW, Hansen JJ, Keku TO, Fodor AA, Jobin C. 2012. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338:120–123. doi: 10.1126/science.1224820. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Buc E, Dubois D, Sauvanet P, Raisch J, Delmas J, Darfeuille-Michaud A, Pezet D, Bonnet R. 2013. High prevalence of mucosa-associated E. coli producing cyclomodulin and genotoxin in colon cancer. PLoS One 8:e56964. doi: 10.1371/journal.pone.0056964. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Bleich RM, Arthur JC. 2019. Revealing a microbial carcinogen. Science 363:689–690. doi: 10.1126/science.aaw5475. [DOI] [PubMed] [Google Scholar]
- 15.Li R, Helbig L, Fu J, Bian X, Herrmann J, Baumann M, Stewart AF, Müller R, Li A, Zips D, Zhang Y. 2018. Expressing cytotoxic compounds in Escherichia coli Nissle 1917 for tumor-targeting therapy. Res Microbiol 170:74–79. doi: 10.1016/j.resmic.2018.11.001. [DOI] [PubMed] [Google Scholar]
- 16.Wassenaar TM. 2018. E. coli and colorectal cancer: a complex relationship that deserves a critical mindset. Crit Rev Microbiol 44:619–632. doi: 10.1080/1040841X.2018.1481013. [DOI] [PubMed] [Google Scholar]
- 17.Pérez-Berezo T, Pujo J, Martin P, Le Faouder P, Galano JM, Guy A, Knauf C, Tabet JC, Tronnet S, Barreau F, Heuillet M, Dietrich G, Bertrand-Michel J, Durand T, Oswald E, Cenac N. 2017. Identification of an analgesic lipopeptide produced by the probiotic Escherichia coli strain Nissle 1917. Nature Commun 8:1314. doi: 10.1038/s41467-017-01403-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Jiang Y, Stornetta A, Villalta PW, Wilson MR, Boudreau PD, Zha L, Balbo S, Balskus EP. 2019. Reactivity of an unusual amidase may explain colibactin's DNA cross-linking activity. J Am Chem Soc 141:11489–11496. doi: 10.1021/jacs.9b02453. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Li ZR, Li J, Cai W, Lai JYH, McKinnie SMK, Zhang WP, Moore BS, Zhang W, Qian PY. 2019. Macrocyclic colibactin induces DNA double-strand breaks via copper-mediated oxidative cleavage. Nat Chem 11:880–889. doi: 10.1038/s41557-019-0317-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Wilson MR, Jiang Y, Villalta PW, Stornetta A, Boudreau PD, Carrá A, Brennan CA, Chun E, Ngo L, Samson LD, Engelward BP, Garrett WS, Balbo S, Balskus EP. 2019. The human gut bacterial genotoxin colibactin alkylates DNA. Science 363:eaar7785. doi: 10.1126/science.aar7785. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Faïs T, Delmas J, Barnich N, Bonnet R, Dalmasso G. 2018. Colibactin: more than a new bacterial toxin. Toxins (Basel) 10:151. doi: 10.3390/toxins10040151. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Brotherton CA, Balskus EP. 2013. A prodrug resistance mechanism is involved in colibactin biosynthesis and cytotoxicity. J Am Chem Soc 135:3359–3362. doi: 10.1021/ja312154m. [DOI] [PubMed] [Google Scholar]
- 23.Zha L, Wilson MR, Brotherton CA, Balskus EP. 2016. Characterization of polyketide synthase machinery from the pks island facilitates isolation of a candidate precolibactin. ACS Chem Biol 11:1287–1295. doi: 10.1021/acschembio.6b00014. [DOI] [PubMed] [Google Scholar]
- 24.Zha L, Jiang Y, Henke MT, Wilson MR, Wang JX, Kelleher NL, Balskus EP. 2017. Colibactin assembly line enzymes use S-adenosylmethionine to build a cyclopropane ring. Nat Chem Biol 13:1063–1065. doi: 10.1038/nchembio.2448. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Brachmann AO, Garcie C, Wu V, Martin P, Ueoka R, Oswald E, Piel J. 2015. Colibactin biosynthesis and biological activity depend on the rare aminomalonyl polyketide precursor. Chem Commun (Camb) 51:13138–13141. doi: 10.1039/c5cc02718g. [DOI] [PubMed] [Google Scholar]
- 26.Guntaka NS, Healy AR, Crawford JM, Herzon SB, Bruner SD. 2017. Structure and functional analysis of ClbQ, an unusual intermediate-releasing thioesterase from the colibactin biosynthetic pathway. ACS Chem Biol 12:2598–2608. doi: 10.1021/acschembio.7b00479. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Li ZR, Li J, Gu JP, Lai JY, Duggan BM, Zhang WP, Li ZL, Li YX, Tong RB, Xu Y, Lin DH, Moore BS, Qian PY. 2016. Divergent biosynthesis yields a cytotoxic aminomalonate-containing precolibactin. Nat Chem Biol 12:773–775. doi: 10.1038/nchembio.2157. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Mousa JJ, Yang Y, Tomkovich S, Shima A, Newsome RC, Tripathi P, Oswald E, Bruner SD, Jobin C. 2016. MATE transport of the E. coli-derived genotoxin colibactin. Nat Microbiol 1:15009. doi: 10.1038/nmicrobiol.2015.9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Cougnoux A, Gibold L, Robin F, Dubois D, Pradel N, Darfeuille-Michaud A, Dalmasso G, Delmas J, Bonnet R. 2012. Analysis of structure-function relationships in the colibactin-maturating enzyme ClbP. J Mol Biol 424:203–214. doi: 10.1016/j.jmb.2012.09.017. [DOI] [PubMed] [Google Scholar]
- 30.Tripathi P, Shine EE, Healy AR, Kim CS, Herzon SB, Bruner SD, Crawford JM. 2017. ClbS is a cyclopropane hydrolase that confers colibactin resistance. J Am Chem Soc 139:17719–17722. doi: 10.1021/jacs.7b09971. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Shine EE, Xue M, Patel JR, Healy AR, Surovtseva YV, Herzon SB, Crawford JM. 2018. Model colibactins exhibit human cell genotoxicity in the absence of host bacteria. ACS Chem Biol 13:3286–3293. doi: 10.1021/acschembio.8b00714. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Reuter C, Alzheimer M, Walles H, Oelschlaeger TA. 2018. An adherent mucus layer attenuates the genotoxic effect of colibactin. Cell Microbiol 20:e12812. doi: 10.1111/cmi.12812. [DOI] [PubMed] [Google Scholar]
- 33.Homburg S, Oswald E, Hacker J, Dobrindt U. 2007. Expression analysis of the colibactin gene cluster coding for a novel polyketide in Escherichia coli. FEMS Microbiol Lett 275:255–262. doi: 10.1111/j.1574-6968.2007.00889.x. [DOI] [PubMed] [Google Scholar]
- 34.Crater DL, Moran CP, Jr. 2001. Identification of a DNA binding region in GerE from Bacillus subtilis. J Bacteriol 183:4183–4189. doi: 10.1128/JB.183.14.4183-4189.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Tronnet S, Garcie C, Rehm N, Dobrindt U, Oswald E, Martin P. 2016. Iron homeostasis regulates the genotoxicity of Escherichia coli that produces colibactin. Infect Immun 84:3358–3368. doi: 10.1128/IAI.00659-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Bian X, Fu J, Plaza A, Herrmann J, Pistorius D, Stewart AF, Zhang Y, Müller R. 2013. In vivo evidence for a prodrug activation mechanism during colibactin maturation. Chembiochem 14:1194–1197. doi: 10.1002/cbic.201300208. [DOI] [PubMed] [Google Scholar]
- 37.Bian X, Plaza A, Zhang Y, Müller R. 2015. Two more pieces of the colibactin genotoxin puzzle from Escherichia coli show incorporation of an unusual 1-aminocyclopropanecarboxylic acid moiety. Chem Sci 6:3154–3160. doi: 10.1039/c5sc00101c. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Healy AR, Wernke KM, Kim CS, Lees NR, Crawford JM, Herzon SB. 2019. Synthesis and reactivity of precolibactin 886. Nat Chem 11:890–898. doi: 10.1038/s41557-019-0338-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Trautman EP, Healy AR, Shine EE, Herzon SB, Crawford JM. 2017. Domain-targeted metabolomics delineates the heterocycle assembly steps of colibactin biosynthesis. J Am Chem Soc 139:4195–4201. doi: 10.1021/jacs.7b00659. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Bonnet M, Buc E, Sauvanet P, Darcha C, Dubois D, Pereira B, Déchelotte P, Bonnet R, Pezet D, Darfeuille-Michaud A. 2014. Colonization of the human gut by E. coli and colorectal cancer risk. Clin Cancer Res 20:859–867. doi: 10.1158/1078-0432.CCR-13-1343. [DOI] [PubMed] [Google Scholar]
- 41.Rasko DA, Rosovitz MJ, Myers GS, Mongodin EF, Fricke WF, Gajer P, Crabtree J, Sebaihia M, Thomson NR, Chaudhuri R, Henderson IR, Sperandio V, Ravel J. 2008. The pangenome structure of Escherichia coli: comparative genomic analysis of E. coli commensal and pathogenic isolates. J Bacteriol 190:6881–6893. doi: 10.1128/JB.00619-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Oshima K, Toh H, Ogura Y, Sasamoto H, Morita H, Park SH, Ooka T, Iyoda S, Taylor TD, Hayashi T, Itoh K, Hattori M. 2008. Complete genome sequence and comparative analysis of the wild-type commensal Escherichia coli strain SE11 isolated from a healthy adult. DNA Res 15:375–386. doi: 10.1093/dnares/dsn026. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Touchon M, Hoede C, Tenaillon O, Barbe V, Baeriswyl S, Bidet P, Bingen E, Bonacorsi S, Bouchier C, Bouvet O, Calteau A, Chiapello H, Clermont O, Cruveiller S, Danchin A, Diard M, Dossat C, Karoui ME, Frapy E, Garry L, Ghigo JM, Gilles AM, Johnson J, Le Bouguénec C, Lescat M, Mangenot S, Martinez-Jéhanne V, Matic I, Nassif X, Oztas S, Petit MA, Pichon C, Rouy Z, Ruf CS, Schneider D, Tourret J, Vacherie B, Vallenet D, Médigue C, Rocha EPC, Denamur E. 2009. Organised genome dynamics in the Escherichia coli species results in highly diverse adaptive paths. PLoS Genet 5:e1000344. doi: 10.1371/journal.pgen.1000344. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Toh H, Oshima K, Toyoda A, Ogura Y, Ooka T, Sasamoto H, Park SH, Iyoda S, Kurokawa K, Morita H, Itoh K, Taylor TD, Hayashi T, Hattori M. 2010. Complete genome sequence of the wild-type commensal Escherichia coli strain SE15, belonging to phylogenetic group B2. J Bacteriol 192:1165–1166. doi: 10.1128/JB.01543-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Chagneau CV, Garcie C, Bossuet-Greif N, Tronnet S, Brachmann AO, Piel J, Nougayrède JP, Martin P, Oswald E. 2019. The Polyamine Spermidine Modulates the Production of the Bacterial Genotoxin Colibactin. mSphere 4:e00414-19. doi: 10.1128/mSphere.00414-19. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Tronnet S, Garcie C, Brachmann AO, Piel J, Oswald E, Martin P. 2017. High iron supply inhibits the synthesis of the genotoxin colibactin by pathogenic Escherichia coli through a non-canonical Fur/RyhB-mediated pathway. Pathog Dis 75:ftx066. doi: 10.1093/femspd/ftx066. [DOI] [PubMed] [Google Scholar]
- 47.Arthur JC, Gharaibeh RZ, Mühlbauer M, Perez-Chanona E, Uronis JM, McCafferty J, Fodor AA, Jobin C. 2014. Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer. Nat Commun 5:4724. doi: 10.1038/ncomms5724. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Hagan EC, Lloyd AL, Rasko DA, Faerber GJ, Mobley HL. 2010. Escherichia coli global gene expression in urine from women with urinary tract infection. PLoS Pathog 6:e1001187. doi: 10.1371/journal.ppat.1001187. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Hancock V, Seshasayee AS, Ussery DW, Luscombe NM, Klemm P. 2008. Transcriptomics and adaptive genomics of the asymptomatic bacteriuria Escherichia coli strain 83972. Mol Genet Genomics 279:523–534. doi: 10.1007/s00438-008-0330-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Nowrouzian FL, Oswald E. 2012. Escherichia coli strains with the capacity for long-term persistence in the bowel microbiota carry the potentially genotoxic pks island. Microb Pathog 53:180–182. doi: 10.1016/j.micpath.2012.05.011. [DOI] [PubMed] [Google Scholar]
- 51.Martin P, Marcq I, Magistro G, Penary M, Garcie C, Payros D, Boury M, Olier M, Nougayrède JP, Audebert M, Chalut C, Schubert S, Oswald E. 2013. Interplay between siderophores and colibactin genotoxin biosynthetic pathways in Escherichia coli. PLoS Pathog 9:e1003437. doi: 10.1371/journal.ppat.1003437. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Arthur JC, Jobin C. 2013. The complex interplay between inflammation, the microbiota and colorectal cancer. Gut Microbes 4:253–258. doi: 10.4161/gmic.24220. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Cougnoux A, Dalmasso G, Martinez R, Buc E, Delmas J, Gibold L, Sauvanet P, Darcha C, Dechelotte P, Bonnet M, Pezet D, Wodrich H, Darfeuille-Michaud A, Bonnet R. 2014. Bacterial genotoxin colibactin promotes colon tumour growth by inducing a senescence-associated secretory phenotype. Gut 63:1932–1942. doi: 10.1136/gutjnl-2013-305257. [DOI] [PubMed] [Google Scholar]
- 54.Dalmasso G, Cougnoux A, Delmas J, Darfeuille-Michaud A, Bonnet R. 2014. The bacterial genotoxin colibactin promotes colon tumor growth by modifying the tumor microenvironment. Gut Microbes 5:675–680. doi: 10.4161/19490976.2014.969989. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Dziubanska-Kusibab PJ, Berger H, Battistini F, Bouwman BAM, Iftekhar A, Katainen R, Cajuso T, Crosetto N, Orozco M, Aaltonen LA, Meyer TF. 2020. Colibactin DNA-damage signature indicates mutational impact in colorectal cancer. Nat Med 2020. doi: 10.1038/s41591-020-0908-2. [DOI] [PubMed] [Google Scholar]
- 56.Pleguezuelos-Manzano C, Puschhof J, Rosendahl Huber A, van Hoeck A, Wood HM, Nomburg J, Gurjao C, Manders F, Dalmasso G, Stege PB, Paganelli FL, Geurts MH, Beumer J, Mizutani T, Miao Y, van der Linden R, van der Elst S, Garcia KC, Top J, Willems RJL, Giannakis M, Bonnet R, Quirke P, Meyerson M, Cuppen E, van Boxtel R, Clevers H, Genomics England Research Consortium. 2020. Mutational signature in colorectal cancer caused by genotoxic pks(+) E. coli. Nature 580:269–273. doi: 10.1038/s41586-020-2080-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Raisch J, Buc E, Bonnet M, Sauvanet P, Vazeille E, de Vallee A, Dechelotte P, Darcha C, Pezet D, Bonnet R, Bringer MA, Darfeuille-Michaud A. 2014. Colon cancer-associated B2 Escherichia coli colonize gut mucosa and promote cell proliferation. World J Gastroenterol 20:6560–6572. doi: 10.3748/wjg.v20.i21.6560. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Gao R, Bouillet S, Stock AM. 2019. Structural basis of response regulator function. Annu Rev Microbiol 73:175–197. doi: 10.1146/annurev-micro-020518-115931. [DOI] [PubMed] [Google Scholar]
- 59.Nasser W, Reverchon S. 2007. New insights into the regulatory mechanisms of the LuxR family of quorum sensing regulators. Anal Bioanal Chem 387:381–390. doi: 10.1007/s00216-006-0702-0. [DOI] [PubMed] [Google Scholar]
- 60.Pappas KM, Weingart CL, Winans SC. 2004. Chemical communication in proteobacteria: biochemical and structural studies of signal synthases and receptors required for intercellular signalling. Mol Microbiol 53:755–769. doi: 10.1111/j.1365-2958.2004.04212.x. [DOI] [PubMed] [Google Scholar]
- 61.Boos W, Böhm A. 2000. Learning new tricks from an old dog: MalT of the Escherichia coli maltose system is part of a complex regulatory network. Trends Genet 16:404–409. doi: 10.1016/s0168-9525(00)02086-2. [DOI] [PubMed] [Google Scholar]
- 62.Ducros VM, Lewis RJ, Verma CS, Dodson EJ, Leonard G, Turkenburg JP, Murshudov GN, Wilkinson AJ, Brannigan JA. 2001. Crystal structure of GerE, the ultimate transcriptional regulator of spore formation in Bacillus subtilis. J Mol Biol 306:759–771. doi: 10.1006/jmbi.2001.4443. [DOI] [PubMed] [Google Scholar]
- 63.Eichenberger P, Fujita M, Jensen ST, Conlon EM, Rudner DZ, Wang ST, Ferguson C, Haga K, Sato T, Liu JS, Losick R. 2004. The program of gene transcription for a single differentiating cell type during sporulation in Bacillus subtilis. PLoS Biol 2:e328. doi: 10.1371/journal.pbio.0020328. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Li H, Durbin R. 2010. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 26:589–595. doi: 10.1093/bioinformatics/btp698. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Tatusova T, DiCuccio M, Badretdin A, Chetvernin V, Nawrocki EP, Zaslavsky L, Lomsadze A, Pruitt KD, Borodovsky M, Ostell J. 2016. NCBI prokaryotic genome annotation pipeline. Nucleic Acids Res 44:6614–6624. doi: 10.1093/nar/gkw569. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Carattoli A, Zankari E, García-Fernández A, Voldby Larsen M, Lund O, Villa L, Møller Aarestrup F, Hasman H. 2014. In silico detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing. Antimicrob Agents Chemother 58:3895–3903. doi: 10.1128/AAC.02412-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Joensen KG, Tetzschner AM, Iguchi A, Aarestrup FM, Scheutz F. 2015. Rapid and easy in silico serotyping of Escherichia coli isolates by use of whole-genome sequencing data. J Clin Microbiol 53:2410–2426. doi: 10.1128/JCM.00008-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O, Aarestrup FM, Larsen MV. 2012. Identification of acquired antimicrobial resistance genes. J Antimicrob Chemother 67:2640–2644. doi: 10.1093/jac/dks261. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Stork C, Kovacs B, Rozsai B, Putze J, Kiel M, Dorn A, Kovacs J, Melegh S, Leimbach A, Kovacs T, Schneider G, Kerenyi M, Emödy L, Dobrindt U. 2018. Characterization of asymptomatic bacteriuria Escherichia coli isolates in search of alternative strains for efficient bacterial interference against uropathogens. Front Microbiol 9:214. doi: 10.3389/fmicb.2018.00214. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Sambrook J, Fritsch EF, Maniatis T. 1989. Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. [Google Scholar]
- 71.Datsenko KA, Wanner BL. 2000. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A 97:6640–6645. doi: 10.1073/pnas.120163297. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Khetrapal V, Mehershahi K, Rafee S, Chen S, Lim CL, Chen SL. 2015. A set of powerful negative selection systems for unmodified Enterobacteriaceae. Nucleic Acids Res 43:e83. doi: 10.1093/nar/gkv248. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Cherepanov PP, Wackernagel W. 1995. Gene disruption in Escherichia coli: TcR and KmR cassettes with the option of Flp-catalyzed excision of the antibiotic-resistance determinant. Gene 158:9–14. doi: 10.1016/0378-1119(95)00193-a. [DOI] [PubMed] [Google Scholar]
- 74.Hilker R, Stadermann KB, Schwengers O, Anisiforov E, Jaenicke S, Weisshaar B, Zimmermann T, Goesmann A. 2016. ReadXplorer 2-detailed read mapping analysis and visualization from one single source. Bioinformatics 32:3702–3708. doi: 10.1093/bioinformatics/btw541. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75.Love MI, Huber W, Anders S. 2014. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15:550. doi: 10.1186/s13059-014-0550-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76.Sharma CM, Hoffmann S, Darfeuille F, Reignier J, Findeiss S, Sittka A, Chabas S, Reiche K, Hackermüller J, Reinhardt R, Stadler PF, Vogel J. 2010. The primary transcriptome of the major human pathogen Helicobacter pylori. Nature 464:250–255. doi: 10.1038/nature08756. [DOI] [PubMed] [Google Scholar]
- 77.Hanahan D. 1983. Studies on transformation of Escherichia coli with plasmids. J Mol Biol 166:557–580. doi: 10.1016/s0022-2836(83)80284-8. [DOI] [PubMed] [Google Scholar]
- 78.Miller VL, Mekalanos JJ. 1988. A novel suicide vector and its use in construction of insertion mutations: osmoregulation of outer membrane proteins and virulence determinants in Vibrio cholerae requires toxR. J Bacteriol 170:2575–2583. doi: 10.1128/jb.170.6.2575-2583.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79.Blattner FR, Plunkett G, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y. 1997. The complete genome sequence of Escherichia coli K-12. Science 277:1453–1462. doi: 10.1126/science.277.5331.1453. [DOI] [PubMed] [Google Scholar]
- 80.Nissle A. 1918. Die antagonistische Behandlung chronischer Darmstörungen mit Colibakterien. Med Klin 2:29–33. [Google Scholar]
- 81.Moriel DG, Bertoldi I, Spagnuolo A, Marchi S, Rosini R, Nesta B, Pastorello I, Corea VA, Torricelli G, Cartocci E, Savino S, Scarselli M, Dobrindt U, Hacker J, Tettelin H, Tallon LJ, Sullivan S, Wieler LH, Ewers C, Pickard D, Dougan G, Fontana MR, Rappuoli R, Pizza M, Serino L. 2010. Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli. Proc Natl Acad Sci U S A 107:9072–9077. doi: 10.1073/pnas.0915077107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 82.Johnson JR, Oswald E, O'Bryan TT, Kuskowski MA, Spanjaard L. 2002. Phylogenetic distribution of virulence-associated genes among Escherichia coli isolates associated with neonatal bacterial meningitis in the Netherlands. J Infect Dis 185:774–784. doi: 10.1086/339343. [DOI] [PubMed] [Google Scholar]
- 83.Chen SL, Hung CS, Xu J, Reigstad CS, Magrini V, Sabo A, Blasiar D, Bieri T, Meyer RR, Ozersky P, Armstrong JR, Fulton RS, Latreille JP, Spieth J, Hooton TM, Mardis ER, Hultgren SJ, Gordon JI. 2006. Identification of genes subject to positive selection in uropathogenic strains of Escherichia coli: a comparative genomics approach. Proc Natl Acad Sci U S A 103:5977–5982. doi: 10.1073/pnas.0600938103. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 84.Skerra A. 1994. Use of the tetracycline promoter for the tightly regulated production of a murine antibody fragment in Escherichia coli. Gene 151:131–135. doi: 10.1016/0378-1119(94)90643-2. [DOI] [PubMed] [Google Scholar]
- 85.Guzman LM, Belin D, Carson MJ, Beckwith J. 1995. Tight regulation, modulation, and high-level expression by vectors containing the arabinose PBAD promoter. J Bacteriol 177:4121–4130. doi: 10.1128/jb.177.14.4121-4130.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 86.Bolivar F, Rodriguez RL, Greene PJ, Betlach MC, Heyneker HL, Boyer HW, Crosa JH, Falkow S. 1977. Construction and characterization of new cloning vehicles. II. A multipurpose cloning system. Gene 2:95–113. doi: 10.1016/0378-1119(77)90000-2. [DOI] [PubMed] [Google Scholar]
- 87.Carver T, Thomson N, Bleasby A, Berriman M, Parkhill J. 2009. DNAPlotter: circular and linear interactive genome visualization. Bioinformatics 25:119–120. doi: 10.1093/bioinformatics/btn578. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 88.Madeira F, Park YM, Lee J, Buso N, Gur T, Madhusoodanan N, Basutkar P, Tivey ARN, Potter SC, Finn RD, Lopez R. 2019. The EMBL-EBI search and sequence analysis tools APIs in 2019. Nucleic Acids Res 47:W636–W641. doi: 10.1093/nar/gkz268. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 89.Drozdetskiy A, Cole C, Procter J, Barton GJ. 2015. JPred4: a protein secondary structure prediction server. Nucleic Acids Res 43:W389–W394. doi: 10.1093/nar/gkv332. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The complete genome sequence of E. coli M1/5 (the chromosome and plasmids pM1-5_30 and pM1-5_120) has been deposited at NCBI GenBank under accession numbers CP053296 to CP053298. All RNA-seq data files are available from the Gene Expression Omnibus database (accession no. GSE143807).